NAV

Tripamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tripamide
DrugBank Accession Number
DB15959
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 369.86
Monoisotopic: 369.0913904
Chemical Formula
C16H20ClN3O3S
Synonyms
  • Tripamide
External IDs
  • ADR-033
  • E-614

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirTripamide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AceclofenacThe therapeutic efficacy of Tripamide can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Tripamide can be decreased when used in combination with Acemetacin.
AcetaminophenTripamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Tripamide is combined with Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Tripamide which could result in a higher serum level.
AclidiniumTripamide may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
AcrivastineTripamide may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
AcyclovirTripamide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.
Albutrepenonacog alfaTripamide may increase the excretion rate of Albutrepenonacog alfa which could result in a lower serum level and potentially a reduction in efficacy.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
G36A0E9CVT
CAS number
73803-48-2
InChI Key
UHLOVGKIEARANS-NIFPGPBJSA-N
InChI
InChI=1S/C16H20ClN3O3S/c17-14-4-3-11(6-15(14)24(18,22)23)16(21)19-20-7-12-9-1-2-10(5-9)13(12)8-20/h3-4,6,9-10,12-13H,1-2,5,7-8H2,(H,19,21)(H2,18,22,23)/t9-,10+,12-,13+
IUPAC Name
N-[(1R,2R,6S,7S)-4-azatricyclo[5.2.1.0^{2,6}]decan-4-yl]-4-chloro-3-sulfamoylbenzamide
SMILES
[H][C@@]12CN(C[C@]1([H])[C@@H]1CC[C@H]2C1)NC(=O)C1=CC=C(Cl)C(=C1)S(N)(=O)=O

References

General References
Not Available
ChemSpider
4445396
ChEBI
32264
Wikipedia
Tripamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0999 mg/mLALOGPS
logP1.89ALOGPS
logP1.13Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)8.85Chemaxon
pKa (Strongest Basic)1.35Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area92.5 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity91.77 m3·mol-1Chemaxon
Polarizability36.35 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 26, 2020 21:59 / Updated at February 21, 2021 18:55